| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Chief Accounting Officer | SVP, Chief Accounting Officer | VP, Corp Controller And CAO
1 company
Calvin Sandra serves as a SVP, Chief Accounting Officer at TVTX. Across recent SEC filings that breaks down to 0 buys and 26 sells. Those positions are worth an estimated $3.0M at current prices.
Historically, Calvin Sandra's trades have earned a middling insider score of 60/100 across 22 rated trades. Over a 12-month horizon, 61.1% of those trades were profitable, with an average 12-month return of -2.5%.
The biggest single holding is TVTX (~$3.0M) as SVP, Chief Accounting Officer. The recent filings there lean toward selling, a net 177,745 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 4,333 | $32.12 | $139,175.96 | -8.1% | +34.3% | - | |
| Dec 24, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 7,402 | $40.00 | $296,080.00 | -16.2% | -33.5% | - | |
| Dec 15, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 2,910 | $36.00 | $104,760.00 | -6.0% | -19.4% | - | |
| Nov 4, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE | 67,115 | $36.00 | $2,416,140.00 | -58.0% | -3.0% | - | |
| Feb 11, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE | 54,244 | $25.00 | $1,356,100.00 | -14.9% | -9.3% | +27.2% | |
| Feb 3, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 3,348 | $20.12 | $67,361.76 | -5.0% | +5.9% | +62.4% | |
| Jan 22, 2025 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 925 | $18.94 | $17,520.24 | -1.7% | -18.4% | +52.8% | |
| Dec 26, 2024 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE | 15,000 | $17.22 | $258,277.50 | -21.5% | +16.9% | +122.9% | |
| Nov 25, 2024 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sale+OE | 12,090 | $18.30 | $221,257.88 | -18.0% | +16.7% | +98.1% | |
| Feb 1, 2024 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 2,820 | $8.53 | $24,057.98 | -5.1% | -30.2% | +137.9% |